Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo.

Gossypol is a naturally occurring polyphenolic compound extracted from cotton plants. Recent studies revealed that gossypol is a non-peptidic small molecule inhibitor of Bcl-2/Bcl-xl. The aim of the present study was to investigate the induction of apoptosis and antitumor effects of gossypol acetate in multiple myeloma and the possible mechanism(s) of action. Our results showed that gossypol acetate resulted in a dose- and time-dependent inhibition of multiple myeloma cell proliferation, with an IC50 value to both U266 and Wus1 cells at 2.4, 2.2 µM at 48 h after treatment. Gossypol acetate effectively induced the apoptosis of multiple myeloma cells as demonstrated by typical morphological changes, DNA ladder formation and increase in the percentage of cells in subdiploid peak. Furthermore, colorimetric assays showed activation of both caspase-3 and caspase-9. Bcl-2 and Bcl-xl expression was decreased by 86.5±1.2% and 35.9±3.6%, respectively, after treatment with gossypol acetate at 25 µmol/l for 24 h. Preliminary studies in vivo showed that a growth inhibition (T/C) of 30.9% (gossypol acetate 40 mg/kg) was obtained in Balb/C mice bearing Wus1 cells. In addition, there was no body weight loss for the treated group in comparison with the vehicle mice. Our results demonstrated that the potent inhibitor of Bcl-2 and Bcl-xl gossypol acetate had significant antiproliferative and antiapoptotic effects on multiple myeloma cells in vitro and in vivo. Gossypol acetate may represent a promising new anticancer agent with a novel molecular mechanism and warrants further investigation as a single agent, or in combination with other chemotherapeutics, for human multiple myeloma with Bcl-2 overexpression.

[1]  G. Morgan,et al.  Guidelines for the diagnosis and management of multiple myeloma 2011 , 2011, British journal of haematology.

[2]  Diane Warren,et al.  A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. , 2006, Blood.

[3]  Robert A Kyle,et al.  Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. , 2005, Blood.

[4]  J. Willey,et al.  Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21waf1/cip1 among human bronchogenic carcinomas , 2005, Molecular Cancer.

[5]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[6]  D. Crouch,et al.  Inactivation of MAP kinase signalling in Myc Transformed Cells and Rescue by LiCl inhibition of GSK3 , 2005, Molecular Cancer.

[7]  Shaomeng Wang,et al.  (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. , 2005, Molecular cancer therapeutics.

[8]  Shaomeng Wang,et al.  Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. , 2005, Molecular cancer therapeutics.

[9]  Shaomeng Wang,et al.  In vitro Effects of the BH3 Mimetic, (−)-Gossypol, on Head and Neck Squamous Cell Carcinoma Cells , 2004, Clinical Cancer Research.

[10]  L. Chiang,et al.  Upregulation of Fas/Fas ligand‐mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line , 2004, Clinical and experimental pharmacology & physiology.

[11]  D. Hou,et al.  Involvement of reactive oxygen species-independent mitochondrial pathway in gossypol-induced apoptosis. , 2004, Archives of biochemistry and biophysics.

[12]  M. Linden,et al.  Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies. , 2004, Blood.

[13]  M. Ergun,et al.  Apoptosis and nitric oxide release induced by thalidomide, gossypol and dexamethasone in cultured human chronic myelogenous leukemic K‐562 cells , 2004, Cell biology international.

[14]  John Calvin Reed,et al.  Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. , 2003, Journal of medicinal chemistry.

[15]  Dajun Yang,et al.  Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. , 2003, Biochemical pharmacology.

[16]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[17]  Y. Gazitt,et al.  Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells. , 2003, Blood.

[18]  A. Kudelka,et al.  An in vitro study of inhibitory activity of gossypol, a cottonseed extract, in human carcinoma cell lines. , 2002, Pharmacological research.

[19]  I. Enyedy,et al.  Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. , 2001, Journal of medicinal chemistry.

[20]  C. Hudis,et al.  Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial , 2001, Breast Cancer Research and Treatment.

[21]  P. Groundwater,et al.  Structure-activity studies on gossypol in tumor cell lines , 2000, Anti-cancer drugs.

[22]  B. Barlogie,et al.  Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.

[23]  M. Reidenberg,et al.  Gossypol Treatment of Recurrent Adult Malignant Gliomas , 1999, Journal of Neuro-Oncology.

[24]  John C Reed,et al.  Bcl-2 family proteins , 1998, Oncogene.

[25]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[26]  C. Thompson,et al.  Bcl-2-family proteins: the role of the BH3 domain in apoptosis. , 1998, Trends in cell biology.

[27]  M. Shelley,et al.  Cytotoxicity of gossypol enantiomers and its quinone metabolite gossypolone in melanoma cell lines , 1997, Melanoma research.

[28]  S. Grant,et al.  Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. , 1994, Cancer research.

[29]  R. Knazek,et al.  Oral gossypol in the treatment of metastatic adrenal cancer. , 1993, The Journal of clinical endocrinology and metabolism.

[30]  L. Larsson,et al.  Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. , 1992, Blood.

[31]  J. Jaroszewski,et al.  Action of gossypol and rhodamine 123 on wild type and multidrug-resistant MCF-7 human breast cancer cells: 31P nuclear magnetic resonance and toxicity studies. , 1990, Cancer research.

[32]  F. W. Cox,et al.  Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers. , 1990, Molecular pharmacology.

[33]  R. Knapp,et al.  Antiproliferative effect of gossypol and its optical isomers on human reproductive cancer cell lines. , 1989, Gynecologic oncology.

[34]  L. Zech,et al.  Cytogenetic studies on human myeloma cell lines , 1987, International journal of cancer.

[35]  S. Korsmeyer,et al.  Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. , 1987, The Journal of clinical investigation.

[36]  M. Oken,et al.  Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. , 1987, The New England journal of medicine.

[37]  G. Tuszynski,et al.  Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines. , 1984, Cancer research.

[38]  Shaomeng Wang,et al.  (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. , 2005, Molecular cancer therapeutics.

[39]  S. Rosati,et al.  Bcl-xl expression in multiple myeloma , 2005, Medical oncology.

[40]  J. Winfield,et al.  In vitro andin vivo cytotoxicity of gossypol against central nervous system tumor cell lines , 2005, Journal of Neuro-Oncology.

[41]  R. Coombes,et al.  A preliminary clinical study of gossypol in advanced human cancer , 2004, Cancer Chemotherapy and Pharmacology.

[42]  S. Kulp,et al.  The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFbeta1) signal transduction pathway. , 2004, Anticancer research.

[43]  R. Mohammad,et al.  Small-molecule inhibitors of Bcl-2 protein , 2004 .